IDEX Biometrics ASA IDXAF
—
0.89
0.00
0.00%
as of 24 Sep
- Market cap
- —
- P/E
- 0.0×
Follow IDXAF
Growth Flags
show if company had growth for consecutive years
| Jun '25 | Mar '25 | Dec '24 | Sep '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
22.22 | 1.45 | 0.10 | 2.31 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.01) | (0.31) | (0.02) | (1.32) | |
P/B ratio |
6.50 | 5.77 | 0.02 | 0.52 | |
Price to Tangible BV |
15.02 | 0.00 | 0.02 | 0.73 | |
EV/Sales |
40.00 | 10.04 | 5.02 | 6.21 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.09) | (0.43) | (0.24) | (0.45) | |
EV/FCF |
(1.11) | (0.43) | (0.24) | (0.46) | |
Quick Ratio |
0.34 | 0.43 | 0.85 | 0.61 | |
Current Ratio |
1.68 | 1.65 | 2.67 | 2.16 | |
Net Debt/EBITDA |
(0.21) | (0.25) | 0.01 | (0.20) | |
Debt/Assets |
18.90% | 19.81% | 19.26% | 15.21% | |
Debt/Equity |
1.75 | 12.58 | 0.42 | 0.34 | |
Asset Turnover |
0.02 | 0.04 | 0.05 | 0.08 | |
Operating CF/Net income |
0.72 | 0.66 | 0.90 | (1.68) | |
Capex/Depreciation |
0.00 | 0.00 | (0.06) | 0.08 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
656.79% | 524.04% | (687.50%) | 2,321.67% | |
Selling, General and Administrative Expense of Revenue |
838.27% | 854.81% | 5,245.83% | 3,096.67% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.06 | 0.12 | |
Share Based Compensation of Revenue |
(206.17%) | (165.38%) | 420.83% | 121.67% | |
Graham Net Nets |
0.02 | (0.93) | 44.27 | 1.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(67.05%) | (2,064.10%) | (17,829.00%) | (579.77%) | |
Free Cash Flow Yield |
(162.62%) | (1,595.64%) | (21,005.16%) | (588.03%) | |
Revenue per Share |
0.00 | 0.01 | 0.01 | 0.02 | |
Operating CF per Share |
(0.05) | (0.33) | (0.81) | (0.73) | |
Capex per Share |
0.00 | 0.00 | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.05) | (0.33) | (0.83) | (0.74) | |
Cash per Share |
0.03 | 0.13 | 0.49 | 0.35 | |
Shareholders Equity per Share |
0.03 | 0.02 | 1.14 | 1.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.03 | 0.02 | 1.14 | 1.83 | |
Free Cash Flow |
(1.49) | (2.72) | (3.42) | (2.31) | |
Working Capital |
3.11 | 3.23 | 5.79 | 5.68 | |
Capital Expenditures |
— | — | (0.08) | (0.03) | |
Net Current Asset Value |
0.13 | (0.77) | 3.67 | 3.31 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 3.25 | 0.50 | |
Net Profit Margin |
(2,555.56%) | (3,984.62%) | (15,500.00%) | 2,266.67% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.31 | 1.71 | 1.43 | 2.27 | |
Average Payables |
1.26 | 0.84 | 0.77 | 1.45 | |
Average Inventory |
5.93 | 5.97 | 5.97 | 6.87 | |
Average Assets |
11.55 | 13.25 | 17.63 | 16.48 | |
Average Common Equity |
1.71 | 3.20 | 8.02 | 9.45 |
Columns are period end dates